Skip to content

Author: Yann Godfrin

AD/PD 2024 – Parkinson Disease (Neuroprotection)

By Yann Godfrin

NX210c PEPTIDE: A PROMISING DRUG CANDIDATE FOR NEUROPROTECTION IN PARKINSON’S DISEASE Sighild Lemarchant1, Juliette Le Douce1, Alexandre Henriques2, Noëlle Callizot2, Yann Godfrin1,3 1Axoltis Pharma, Lyon, France 2Neuro-Sys, Gardanne, France 3Godfrin Life-Sciences, Caluire-et-Cuire, France Objectives PD is characterized by the accumulation of α-synuclein and blood-brain barrier disruption, thereby contributing to the loss of dopaminergic neurons in … Continued

Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c

By Yann Godfrin

Phase II trial will assess efficacy and tolerability of NX210c in Amyotrophic Lateral Sclerosis (ALS) patients 80 patients due to be enrolled with first results expected in early 2026 NX210c drug candidate allows for promising approach to repairing Blood Brain Barrier (BBB) which is impaired in neurodegenerative diseases such as ALS Read more (Download PDF … Read more

Axoltis Pharma presents promising results from phase 1b clinical trial of innovative drug candidate for neurodegenerative diseases

By Yann Godfrin

Good safety profile and significant pharmacological effects confirmNX210c drug candidate properties and potential to address broad range of neurodegenerative diseases Biomarkers reveal significant and sustained effects confirming NX210c’saction on integrity and repair of Blood Brain Barrier (BBB), as well as fundamental pathways in neuroprotection and neurotransmission In 2024, Axoltis plans to initiate phase 2 trial … Read more

InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders

By Yann Godfrin

July 27th, 2023 Milan, Lyon InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a collaborative partnership with Axoltis Pharma, a biopharmaceutical company committed to developing disease-modifying drugs for patients with high unmet medical needs in neurodegenerative and traumatic neurologic impairments. This strategic collaboration … Read more